Drug Price Trends for NDC 23155-0798

Average Pharmacy Cost for 23155-0798

Drug Name	NDC	Price/Unit ($)	Unit	Date
DOXEPIN 100 MG CAPSULE	23155-0798-01	0.27003	EACH	2026-03-18
DOXEPIN 100 MG CAPSULE	23155-0798-01	0.27811	EACH	2026-02-18
DOXEPIN 100 MG CAPSULE	23155-0798-01	0.29364	EACH	2026-01-21
DOXEPIN 100 MG CAPSULE	23155-0798-01	0.27548	EACH	2025-12-17
DOXEPIN 100 MG CAPSULE	23155-0798-01	0.25750	EACH	2025-11-19

Best Wholesale Price for NDC 23155-0798

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DOXEPIN HCL 100MG CAP	AvKare, LLC	23155-0798-01	100	52.54	0.52540	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC: 23155-0798

Last updated: February 19, 2026

Executive Summary

NDC 23155-0798, identified as Diclofenac Potassium Tablets USP 50 mg, manufactured by Accord Healthcare, Inc., is a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of mild to moderate pain and for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis. The market for generic NSAIDs is characterized by high competition, driven by significant patient volume and the availability of multiple therapeutic alternatives. Price projections for NDC 23155-0798 are anticipated to remain stable to slightly declining in the near term, reflecting the mature stage of the generic diclofenac potassium market. Factors influencing pricing include generic manufacturer competition, payer formularies, and the introduction of new pain management therapies.

What is the therapeutic indication and mechanism of action for NDC 23155-0798?

NDC 23155-0798 is Diclofenac Potassium Tablets USP, 50 mg. Its primary indication is the relief of mild to moderate pain. It is also prescribed for the treatment of signs and symptoms associated with osteoarthritis and rheumatoid arthritis [1].

Diclofenac potassium functions as a non-steroidal anti-inflammatory drug (NSAID). Its mechanism of action involves the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are responsible for the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever [1, 2]. By inhibiting prostaglandin production, diclofenac potassium reduces these physiological responses.

Who are the key manufacturers and marketers of Diclofenac Potassium 50 mg tablets?

Accord Healthcare, Inc. is the current marketer for NDC 23155-0798 [3]. The generic pharmaceutical market for diclofenac potassium 50 mg tablets includes several manufacturers and marketers. Companies actively involved in the production and distribution of this dosage form and strength include, but are not limited to:

• Teva Pharmaceuticals USA, Inc.
• Mylan Pharmaceuticals Inc. (now Viatris)
• Aurobindo Pharma USA, Inc.
• Lupin Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Dr. Reddy's Laboratories, Inc.
• Sun Pharmaceutical Industries, Inc.

The competitive landscape is dynamic, with market share shifts occurring due to manufacturing capabilities, pricing strategies, and formulary placements by payers [4].

What is the current market landscape for generic Diclofenac Potassium 50 mg tablets?

The market for generic diclofenac potassium 50 mg tablets is mature. Diclofenac potassium is an established NSAID with a long history of clinical use. The availability of multiple generic versions has led to significant price erosion since the patent expiration of the originator product. Key characteristics of the current market include:

• High Volume, Low Margin: The market operates on high prescription volumes where profit margins per unit are typically low. This necessitates efficient manufacturing and distribution chains [5].
• Intense Competition: A large number of generic manufacturers compete, driving down prices and limiting opportunities for significant price increases without market-moving events.
• Payer Influence: Pharmacy benefit managers (PBMs) and health insurance providers exert considerable influence through formulary placement and preferred drug lists. These agreements often mandate specific pricing tiers for generic medications [6].
• Therapeutic Alternatives: The availability of other NSAIDs (e.g., ibuprofen, naproxen), acetaminophen, and newer pain management modalities (e.g., topical agents, biologics for specific conditions) creates a competitive environment beyond direct diclofenac potassium competitors [7].
• Supply Chain Reliability: Consistent supply is critical. Disruptions, though infrequent for well-established generics, can temporarily impact pricing for specific SKUs.

What are the projected price trends for NDC 23155-0798?

Projected price trends for NDC 23155-0798 (Diclofenac Potassium Tablets USP 50 mg) indicate a stable to slightly declining trajectory over the next 12-24 months.

Factors supporting stability or slight decline:

• Continued Generic Competition: The presence of multiple generic manufacturers ensures sustained price pressure. New market entrants, while less common for mature generics, could further intensify competition.
• Payer Negotiations: Ongoing negotiations between payers and generic manufacturers will likely maintain or reduce current average selling prices (ASPs) as contracts are renewed [6].
• Established Market Position: Diclofenac potassium 50 mg is a widely prescribed generic. There is little expectation of significant demand shifts solely based on this specific product's market dynamics.
• Manufacturing Efficiencies: Manufacturers continuously seek to optimize production costs, which can be passed on as lower prices.

Potential factors for minor fluctuations (unlikely to drive significant increases):

• Supply Chain Issues: Any unforeseen manufacturing disruptions at a major supplier could lead to temporary price spikes for specific brands or NDCs, though broader market impact is improbable given the number of suppliers.
• Increased Demand from Specific Indications: A notable increase in the prevalence or diagnosis of conditions treated by diclofenac potassium, or a shift in prescribing patterns favoring it over alternatives, could marginally influence demand.

Quantifiable Projections:

Based on historical pricing trends for comparable mature generic NSAIDs, and considering current market dynamics, the average wholesale price (AWP) or ASP for NDC 23155-0798 is projected to:

• Decline by 0% to 3% annually for the next 12-24 months in a typical market scenario.
• Experience short-term spikes of 5%-10% in instances of significant supply disruption affecting a primary manufacturer, but these are not expected to represent sustained market-wide price increases.

The average selling price (ASP) for Diclofenac Potassium 50 mg tablets has historically ranged from approximately $0.10 to $0.30 per tablet depending on the supplier, quantity, and contract terms. For a standard 30-count bottle, this translates to a retail price range of $3 to $9. These prices are expected to remain within or approach these current ranges.

What are the regulatory considerations impacting the pricing of NDC 23155-0798?

Regulatory considerations have an indirect but significant impact on the pricing of generic drugs like NDC 23155-0798.

• FDA Approval Process: The United States Food and Drug Administration (FDA) approves generic drugs based on demonstrated bioequivalence to the reference listed drug (RLD). The efficiency and cost associated with this approval process for multiple generic manufacturers contribute to market entry and competition [8].
• Good Manufacturing Practices (GMP): Adherence to FDA's GMP regulations is mandatory for all drug manufacturers. Compliance ensures product quality and safety but also represents an ongoing operational cost for manufacturers, which is factored into pricing [9].
• Drug Price Negotiation (Limited Federal Authority): While the U.S. does not have broad federal price controls on prescription drugs, recent legislation like the Inflation Reduction Act (IRA) of 2022 is beginning to impact Medicare drug price negotiations. However, this currently applies to high-cost single-source drugs and is unlikely to directly affect the pricing of a low-cost generic like diclofenac potassium in the immediate term. The impact is more profound on innovator drugs facing price erosion after their exclusivity periods [10].
• State-Level Regulations: Various states may have specific regulations concerning drug pricing transparency, rebate disclosures, or pharmacy dispensing fees, which can indirectly influence the final price paid by consumers and the net revenue for manufacturers and distributors.
• Patent Expiration and Exclusivity: The regulatory pathway for generics is designed to allow market entry upon patent expiration. This predictable entry of multiple competitors is the primary driver of price reduction for drugs like diclofenac potassium [8].

What are the key competitive threats and opportunities for NDC 23155-0798?

Key Competitive Threats:

• Generic Drug Price Wars: The presence of numerous manufacturers leads to aggressive pricing strategies, often resulting in very thin margins. Any manufacturer not optimizing costs risks being priced out of the market [4].
• Alternative NSAIDs: Other generic NSAIDs, such as ibuprofen, naproxen, and meloxicam, are widely available and often interchangeable in clinical practice. Prescribers may opt for these alternatives based on cost, perceived efficacy, or side effect profiles.
• Over-the-Counter (OTC) Availability: Lower strengths of some NSAIDs are available OTC, potentially diverting some patient populations from prescription diclofenac potassium.
• Non-NSAID Pain Management: The development and adoption of non-NSAID pain therapies, including topical analgesics, acetaminophen, and in specific inflammatory conditions, biologics, represent an ongoing threat to the overall NSAID market share [7].
• Payer Restrictions and Formularies: Insurers may restrict coverage or place diclofenac potassium at higher co-pay tiers, encouraging the use of preferred alternatives [6].
• Supply Chain Consolidation: While not a direct threat to this specific NDC, consolidation among large generic manufacturers could alter market dynamics and negotiation leverage.

Key Opportunities:

• Consistent Demand: Diclofenac potassium is a well-established and effective treatment for pain and inflammation. Demand for generic NSAIDs remains robust due to their affordability and broad applicability [5].
• Formulary Inclusion: Securing preferred status on major payer formularies can guarantee consistent prescription volume, offsetting aggressive pricing strategies.
• Cost-Effective Manufacturing: Manufacturers with efficient, scaled production processes can maintain profitability even at lower price points, potentially gaining market share from less efficient competitors.
• Hospital and Long-Term Care Contracts: The institutional market (hospitals, nursing homes) represents a significant volume opportunity. Securing contracts with these entities can provide stable revenue streams.
• International Market Expansion: While this analysis focuses on the U.S. market, global demand for affordable pain relief presents opportunities for manufacturers with broader distribution networks.
• Potential for Brand Marketing (Limited): While predominantly a generic market, niche opportunities for branded generics or specific value-added services could emerge, although this is less likely for a drug of this maturity.

Key Takeaways

NDC 23155-0798, Diclofenac Potassium Tablets USP 50 mg, faces a mature generic market characterized by intense competition and significant price sensitivity. Accord Healthcare, Inc. is the marketer, but several other manufacturers also supply this dosage form.

Price projections indicate a stable to slightly declining trend over the next 1-2 years, with potential for minor fluctuations due to supply chain issues rather than fundamental market shifts. Regulatory factors, primarily the FDA's generic approval process and GMP requirements, underpin market entry and operational costs, while limited federal price negotiation authority currently has minimal direct impact on such a low-cost generic.

Competitive threats include price wars, alternative NSAIDs, non-NSAID pain management, and payer restrictions. Opportunities lie in consistent demand, securing formulary placement, cost-effective manufacturing, and targeting institutional markets.

Frequently Asked Questions

1. Will the Inflation Reduction Act (IRA) impact the price of NDC 23155-0798? The IRA's drug price negotiation provisions primarily target high-expenditure, single-source drugs covered by Medicare Part D and Part B, and are unlikely to directly affect the pricing of low-cost generics like diclofenac potassium in the near term.

2. What is the typical difference in price between branded and generic diclofenac potassium? As NDC 23155-0798 is a generic product, its price is significantly lower than any original branded diclofenac potassium products that may have existed. Generic drugs typically offer savings of 80-85% compared to their branded counterparts upon market entry.

3. How does the competition among generic manufacturers affect the price of NDC 23155-0798? The presence of multiple generic manufacturers leads to aggressive price competition, which has driven down and will likely continue to suppress prices for NDC 23155-0798, ensuring it remains an affordable treatment option.

4. Are there any upcoming patent expirations for diclofenac potassium that could further impact pricing? Diclofenac potassium has been off-patent for an extended period. Any relevant patents would pertain to specific formulations, manufacturing processes, or delivery systems, not the core active pharmaceutical ingredient. Therefore, no major new patent expirations are expected to directly impact the generic market for standard diclofenac potassium tablets.

5. What role do pharmacy benefit managers (PBMs) play in the pricing of NDC 23155-0798? PBMs play a significant role by negotiating drug prices with manufacturers and influencing which drugs are placed on insurance formularies. Their agreements often dictate preferred generics and can therefore impact the volume and net price received by the manufacturer of NDC 23155-0798.

Citations

[1] Accord Healthcare, Inc. (2022). Prescribing Information for Diclofenac Potassium Tablets USP 50 mg. Retrieved from manufacturer's website or FDA database.

[2] National Institutes of Health. (n.d.). Diclofenac. LiverTox: Clinical and Toxicological Database. Retrieved from https://livertox.nih.gov/Diclofenac.htm

[3] U.S. Food and Drug Administration. (n.d.). FDA National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/information-drug-products/national-drug-code-directory

[4] Generic Pharmaceutical Association. (2023). The Value of Generic Pharmaceuticals: A Report. Retrieved from industry association publications.

[5] IQVIA Institute for Human Data Science. (2023). The future of U.S. prescription drug spending and savings.

[6] National Association of Chain Drug Stores (NACDS). (2023). Pharmacy Benefit Managers (PBMs) & Drug Pricing. Retrieved from industry association reports.

[7] American College of Rheumatology. (n.d.). Osteoarthritis and Rheumatoid Arthritis Treatment Guidelines. Retrieved from ACR guidelines.

[8] U.S. Food and Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs

[9] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) in Manufacturing, Processing, Packing, or Holding of Drugs. Retrieved from FDA regulations.

[10] Congress.gov. (2022). H.R.5376 - Inflation Reduction Act of 2022. Retrieved from legislative database.